Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Capital Expenditures (2023 - 2025)

Historic Capital Expenditures for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $1.1 million.

  • Immunome's Capital Expenditures fell 2748.54% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 650.41%. This contributed to the annual value of $7.2 million for FY2024, which is 76317.69% up from last year.
  • Immunome's Capital Expenditures amounted to $1.1 million in Q3 2025, which was down 2748.54% from $905000.0 recorded in Q2 2025.
  • In the past 5 years, Immunome's Capital Expenditures registered a high of $3.7 million during Q1 2025, and its lowest value of $36000.0 during Q3 2023.
  • Its 3-year average for Capital Expenditures is $1.2 million, with a median of $1.1 million in 2025.
  • Per our database at Business Quant, Immunome's Capital Expenditures surged by 417500.0% in 2024 and then crashed by 6139.08% in 2025.
  • Over the past 3 years, Immunome's Capital Expenditures (Quarter) stood at $349000.0 in 2023, then skyrocketed by 222.64% to $1.1 million in 2024, then dropped by 0.89% to $1.1 million in 2025.
  • Its Capital Expenditures stands at $1.1 million for Q3 2025, versus $905000.0 for Q2 2025 and $3.7 million for Q1 2025.